✦ LIBER ✦

Recurrent pyrexia, cough and dyspnoea with hydroxyurea

✍ Scribed by GRACE, R. F. ;SHENFIELD, G. M. ;GRANT, J. ;RAVICH, R.

Book ID: 108999902
Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 121 KB
Volume: 28
Category: Article
ISSN: 0004-8291
DOI: 10.1111/j.1445-5994.1998.tb01963.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A patient with cough and dyspnoea (2007:

A patient with cough and dyspnoea (2007: 4a)

📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 95 KB

Colonic malignancy with recurrent bacter

Colonic malignancy with recurrent bacteraemia presenting as pyrexia of unknown origin

✍ G. M. Varghese; M. Shenoy; S. Subramanian; S. Peter; D. Mathai 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Treatment of recurrent head and neck can

Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation

✍ Burkhard Weppelmann; Richard H Wheeler; Glenn E Peters; Robert Y Kim; Sharon A S 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 799 KB

A 64-year-old man with chronic cough and

A 64-year-old man with chronic cough and recurrent respiratory infections

✍ Welmoed Reitsma; Martin J. Visser; Folgert de Vries; Peter van Hengel 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 624 KB

Recurrent cough and hemoptysis associate

Recurrent cough and hemoptysis associated with tracheal capillary hemangioma in an adolescent boy: A case report

✍ Ilias Porfyridis; Charalambos Zisis; Konstantinos Glinos; Krystallia Stavrakaki; 📂 Article 📅 2007 🏛 CTSNet 🌐 English ⚖ 494 KB

Treatment of metastatic and recurrent ce

Treatment of metastatic and recurrent cervix cancer with chemotherapy: A randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate

✍ Bezwoda, W. R. ;Nissenbaum, M. ;Derman, D. P. 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

In a randomised trial comparing singleagent chemotherapy (hydroxyurea) to combination chemotherapy in advanced cervix cancer, response was seen in 57% (including 13% CR) of patients receiving the combination (DDP + MTX) regimen. Responding patients survived significantly longer (11 months) than eith